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ABSTRACT
Background: The goal of this prospective multicentric trial was to validate a 
technique that allowed for MGMT promoter methylation analysis in routine clinical 
practice.
Methods: The MGMT status of 139 glioblastoma patients, whom had received 
standard first line treatment, was determined using pyrosequencing (PSQ) and a 
semi-quantitative Methylation-specific PCR (sqMS-PCR) method, using both frozen 
and formalin-fixed paraffin-embedded FFPE samples. Eight participating centers 
locally performed the analysis, including external quality controls.
Results: There was a strong correlation between results from FFPE and frozen 
samples. With cut-offs of 12% and 13%, 98% and 91% of samples were identically 
classified with PSQ and sqMS-PCR respectively. In 12% of cases frozen samples 
were excluded because they had a low percentage of tumor cells. In 5-6% of cases 
the analysis was not feasible on FFPE samples. The optimized risk cut-offs were 
higher in both techniques when using FFPE samples, in comparison to frozen samples. 
For sqMS-PCR, we validated a cut-off between 13-15% to dichotomize patients. For 
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PSQ, patients with a low level of methylation (<= 8%) had a median progression-
free survival under 9 months, as compared with more than 15.5 months for those 
with a level above 12%. For intermediate values (9-12%), more discordant results 
between FFPE and frozen samples were observed and there was not a clear benefit 
of temozolomide treatment, which indicated a “grey zone”.
Conclusions: MGMT status can reliably be investigated in local laboratories. PSQ 
is the ideal choice as proven by strong interlaboratory reproducibility, along with 
threshold agreements across independent studies.
INTRODUCTION
Since the introduction of temozolomide 
(TMZ) chemotherapy in the standard care protocol 
for glioblastoma (GBM) patients, MGMT promoter 
methylation analysis has become a crucial biological 
marker. As MGMT promoter methylation is recognized as 
a very powerful predictor of response to TMZ for newly 
diagnosed GBM patients, it is used to stratify or select 
patients in clinical trials [1, 2]. Moreover, the most recent 
recommendation in the EANO guideline was that MGMT 
testing should be standard practice specifically for elderly 
patients as, in combination with performance status, it 
could help clinicians selecting the appropriate treatment 
for these patients [3]. The routine implementation of 
MGMT testing to aid decision making in GBM patients 
raises complex issues, including the choice of the optimal 
molecular test (for review 1) [1].
The two most popular and validated techniques 
to assess MGMT status are, quantitative Methylation-
Specific PCR (Q-MSP) [4–6] and pyrosequencing 
(PSQ) [6–12]. The Q-MSP technique that has been used 
in several international clinical trials determines the 
number of copies of methylated MGMT, which is then 
normalized to the number of copies of the ACTB gene. 
PSQ is a technique based on the principle of sequencing-
by-synthesis that quantifies DNA methylation levels at 
individual selected CpG sites. Approximately, 30% of 
GBM patients are classified as “methylated” with Q-MSP 
[4, 5] as compared to about 45% with PSQ [6, 7, 10].
A crucial factor for a clinical setting method is 
a high degree of repeatability and reproducibility. To 
be reliable for a clinical use, a technique must display 
a high repeatability and reproducibility. Repeatability 
represents the degree of agreement among repeated 
measurements obtained for one identical sample, in one 
laboratory, on a single apparatus, with the same operator; 
while reproducibility signifies the degree of agreement 
among repeated measurements, obtained under different 
conditions, in different laboratories for one identical 
sample. Reproducibility indicates the robustness of the test, 
which is extremely important for techniques implemented 
in multiple laboratories. Additionally, it is important to 
consider the validation cut-off points. There is a span of 
MGMT methylation measurements in clinical samples, 
ranging from very low (limit of detection of the technique) 
to very high. To classify samples as “methylated” or 
“unmethylated”, occasionally a mathematical cut-off will 
be utilized. Authors have reported a bimodal distribution 
for MGMT methylation measurements with Q-MSP and 
considered a cut-off the minimum value between the two 
distributions [13]. Alternatively, other authors have based 
the cut-off on values obtained in non-neoplastic brain 
samples (mean of normal brain samples +/- two standard 
deviations) [8]. Intuitively, the optimal cut-off would be the 
minimal MGMT methylation that is able to suppress MGMT 
expression. This is able to be investigated by utilizing cell 
lines and comparing MGMT methylation and MGMT 
expression. However this biological cut-off would not take 
into account the complexity of GBM samples that may 
contain a variable number of non-neoplastic cells whose 
“unmethylated” MGMT DNA is extracted with that of tumor 
cells. This variable could lead to an underestimation of the 
level of MGMT methylation of the tumor cells [14]. This 
can be overcome by macrodissection of samples to ensure a 
high percentage of tumor cells. However, selecting an area 
rich in cancer cells can be challenging: recent studies have 
shown the difficulty to accurately assess the percentage of 
tumor cells [15, 16]. Moreover, in GBM samples non-tumor 
and tumor cells are often intermingled together. Thus, a 
compromise would be to establish on outcome-based cut-
off that needs to be validated in multiple cohorts of patients, 
ideally prospectively.
In a previous study we demonstrated that PSQ was 
the most optimal technique among the five that were tested 
[10]. We have extended our analysis into a prospective 
study. 163 GBM patients were enrolled in 8 centers and 
MGMT testing was performed in each center on both 
frozen and FFPE samples. As PSQ requires a specific piece 
of equipment, which is not always available in molecular 
laboratories, we also investigated using an alternative 
fluorescent semi-quantitative methylation-specific PCR 
(sqMS-PCR) [17]. The goal of this study was to validate 
a method that allows for the quantification of MGMT 
methylation in routine clinical practice and to establish 
clinical cut-offs. We show that MGMT status can reliably 
be investigated in local laboratories. PSQ is the ideal 
choice as proven by strong interlaboratory reproducibility. 
We recommend a classification of MGMT promoter 
methylation status in three subgroups: “unmethylated” (0-
8%), “methylated” (13-100%) and a grey zone for patients 
with intermediate values (9-12%).
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RESULTS
Study population
Among the 163 patients enrolled in the study, 14 
were excluded due to non-compliance of the inclusion 
criteria. 10 additional patients were excluded because 
they had not received TMZ (n=3) or there was no 
sample to be tested (n=7) (Figure 1). Clinical patient 
characteristics are summarized in Table 1. A total 
of 119 (85.6%) patients died once the database was 
closed. The median PFS was 9.5 months (8.9 – 11.2; 
95% CI) and the median OS was 20.0 months (18.3 – 
22.6; 95% CI).
Analysis of reproducibility
As repeatability has been previously reported for 
the two techniques [10, 17], only reproducibility was 
tested in this study. DNA from 3 cell lines (RNS85, 
RNS96 and RNS175), were used as external quality 
controls, to assess interlaboratory reproducibility. Each 
control was tested in at least duplicate in the different 
participating laboratories. The mean values for RNS85 
were 6% (range: 3-10%, n=22) by PSQ and 13% (range: 
1-31%, n=20) by sqMS-PCR. The mean values for 
RNS175 were 18% (range: 14-22%, n=22) by PSQ and 
90% (range: 64-100%, n=19) by sqMS-PCR. The mean 
values for RNS96 were 36% (range: 33-39%, n=22) by 
PSQ and 69% (range: 47-79%, n=19) by sqMS-PCR. 
RNS85 level of methylation was close to the limits of 
quantification previously published for PSQ (4%) [10] 
and sqMS-PCR (15%) [17]. The reproducibility CV 
was 25% (with PSQ) and 55% (with sqMS-PCR) for 
RNS85. The CV of RNS175 was 11% (PSQ) and 8% 
sqMS-PCR and 5% (PSQ) and 12% (sqMS-PCR) for 
RNS96 (Figure 2).
Comparison of MGMT methylation results on 
FFPE and fresh frozen samples
Figure 1 shows that 12% (15/127) of frozen samples 
were determined to have less than 40% of tumor cells 
and therefore, were removed from this study. The PSQ 
method was shown to be feasible on all frozen samples 
available, in comparison to 4 failure analyses occurring 
when using the sqMS-PCR method. Failure analysis was 
more frequent in FFPE samples (7 and 8 cases respectively 
for PSQ and sqMS-PCR). The median percentages of 
methylation were 7% when using PSQ on 112 frozen 
samples (range 1-84%) and 9% on 121 FFPE samples 
(range 1-92%). Furthermore, the median percentages of 
methylation were 11% when using sqMS-PCR on 108 
frozen samples (range 0-83%) and 0% for sqMS-PCR on 
118 FFPE samples (range 0-91%) (Figure 3a). A strong 
correlation was observed for the 95 samples analyzed by 
the PSQ method, as well as, the 93 samples analyzed using 
the sqMS-PCR method with DNA extracted from FFPE 
and frozen samples (Figure 3b/3c).
Figure 1: Prospective Multicentre Study Patient Profile.
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Figure 2: Box plot representation of results of the 3 controls (RNS85, RNS175 and RNS96) tested by pyrosequencing 
(PSQ) and semi-quantitative Methylation-specific PCR sqMS-PCR. Each control was repeated at least in duplicate at each of 
the participating laboratories. The box plots depict the minimum and maximum values observed, the upper (Q3) and lower (Q1) quartiles 
(the length of the box represents the interquartile range), the median (identified by a line inside the box) and the mean (identified by the 
black point). Above each box the coefficient of variation (CV) estimates the interlaboratory reproducibility of the technique at the observed 
value.
Table 1: Patient characteristics 
Median age at surgery in years (range) 55.9 (23.0 – 71.0)
Gender, n  
 Females 41
 Males 98
Type of surgery, n  
 Total resection 78
 Partial resection 41
 Biopsy 20
KPS, n  
 90-100 41
 70 – 80 76
 < 70 20
 Missing 2
Cycles of TMZ in adjuvant, n  
 Median (range) 6 (0-30)
Oncotarget5www.impactjournals.com/oncotarget
Predictive impact of different cut-off values of 
MGMT Methylation
Threshold values to separate low- and high-risk 
patients according to their outcomes were determined for 
each technique and type of sample. Table 2a displays the 
best cut-offs for OS as 6% for PSQ on frozen samples, 
16% for PSQ on FFPE samples, 13% for sqMS-PCR on 
frozen samples and 23% for sqMS-PCR on FFPE samples. 
Additionally, Table 2b displays the best cut-offs for PFS. 
Optimized cut-offs were higher in both techniques when 
using FFPE samples compared to frozen samples, despite 
the lack of a systematic higher value being observed with 
this type of sample (Bland-Altman plot- (Figure 3)).
To determine a cut-off that would be appropriate for 
both sample types, we tested the concordance (that means 
the percentage of patients identically classified from 
frozen and FFPE samples) for each combination of cut-
offs between 6% and 16% for PSQ and between 13% and 
23% for sqMS-PCR. With the two different optimized cut-
Figure 3: Comparison of results obtained on FFPE and frozen samples. a. distribution of data according to the technique and 
the type of sample. b-e. agreement between frozen and FFPE samples for PSQ (b and d) and sqMS-PCR (c and e) analysis using Bland-
Altman (d and e) or scatter plots (b and c).
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Table 2: Comparison of various prognostic impacts when evaluating MGMT promoter methylation using 
pyrosequensing (PSQ) and a semi-quantitative methylation-specific PCR (sqMS-PCRS) from frozen or FFPE samples
a/OS
Type of 
analysis type of cut-off cut-off value
% of patients 
with a methylated 
MGMT promoter
HR p AUCROC CHarrell
PSQ/FFPE
optimized cut-off 
(current series/FFPE 
samples)
16 39 0,22 <1,00E-
06
0,70 0,71
PSQ/frozen
optimized cut-off 
(current series/frozen 
samples)
6 51 0,25
<1,00E-
06
0,69 0,70
PSQ/frozen
optimized cut-off 
(previous series/
frozen samples)
8 49 0,28 <1,00E-
06
0,69 0,69
PSQ/FFPE
best level of 
concordance 
between frozen and 
FFPE samples
13 40 0,23 <1,00E-
06
0,69 0,70
PSQ/frozen
best level of 
concordance 
between frozen and 
FFPE samples
12 or 13 44 0,29 <1,00E-
06
0,69 0,70
PSQ/FFPE
best level of 
concordance 
between frozen and 
FFPE samples
12 41 0,24 <1,00E-
06
0,69 0,70
PSQ/FFPE
optimized cut-off 
(previous series/
frozen samples)
8 51 0,25 <1,00E-
06
0,68 0,70
PSQ/frozen
optimized cut-off 
(current series/FFPE 
samples)
16 40 0,32 3,00E-06 0,68 0,69
qMS-PCR/
FFPE
optimized cut-off 
(current series/FFPE 
samples)
23 31 0,24 <1,00E-
06
0,68 0,69
qMS-PCR/
frozen
optimized cut-off 
(current series/frozen 
samples) and best 
level of concordance 
between frozen and 
FFPE samples
13 45 0,35 1,20E-05 0,67 0,67
qMS-PCR/
FFPE
best level of 
concordance 
between frozen and 
FFPE samples
12 40 0,3 <1,00E-
06
0,67 0,67
PSQ/FFPE
optimized cut-off 
(current series/frozen 
samples)
6 59 0,31
<1,00E-
06
0,66 0,68
(Continued)
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a/OS
Type of 
analysis type of cut-off cut-off value
% of patients 
with a methylated 
MGMT promoter
HR p AUCROC CHarrell
qMS-PCR/
FFPE
best level of 
concordance 
between frozen and 
FFPE samples
13 37 0,3 <1,00E-
06
0,66 0,67
qMS-PCR/
frozen
optimized cut-off 
(current series/FFPE 
samples)
23 38 0,46 8,87E-04 0,65 0,64
b/PFS
Type of 
analysis type of cut-off cut-off value
% of patients 
with a methylated 
MGMT promoter
HR p AUCROC CHarrell
PSQ/frozen
optimized cut-off for 
PFS (current series/
frozen samples)
15 43 0,3
<1,00E-
06
0,66 0,64
PSQ/frozen
optimized cut-off for 
OS (current series/
frozen samples)
6 51 0,27
<1,00E-
06
0,66 0,63
PSQ/frozen
best level of 
concordance 
between frozen and 
FFPE samples
12 or 13 44 0,31 1,00E-06 0,66 0,63
PSQ/frozen
optimized cut-off for 
OS (previous series/
frozen samples)
8 49 0,32 1,00E-06 0,66 0,63
PSQ/FFPE
optimized cut-off for 
PFS (current series/
FFPE samples)
19 38 0,3 <1,00E-
06
0,66 0,63
PSQ/FFPE
optimized cut-off for 
OS (current series/
FFPE samples)
16 39 0,31 <1,00E-
06
0,65 0,62
PSQ/FFPE
best level of 
concordance 
between frozen and 
FFPE samples
13 40 0,31 <1,00E-
06
0,65 0,62
PSQ/FFPE
best level of 
concordance 
between frozen and 
FFPE samples
12 41 0,32 1,00E-06 0,65 0,62
PSQ/frozen
optimized cut-off for 
OS (current series/
FFPE samples)
16 40 0,37 1,40E-05 0,65 0,62
PSQ/FFPE
optimized cut-off for 
OS (previous series/
frozen samples)
8 51 0,36 3,00E-06 0,64 0,61
(Continued)
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offs for PSQ, 92% of patients were identically classified, 
while 8 patients out of 95 exhibited conflicting results. 
When using sqMS-PCR, 87% of patients were identically 
classified, while 12 patients out of 93 displayed conflicting 
results. At a cut-off of 12% or 13% for PSQ, 98% of 
patients had identical methylation status, irrespective of 
the type of sample used in the analysis. The optimized cut-
off of 13% for sqMS-PCR, allowed the best concordance 
of 91%. Utilizing these two cut-offs on the 88 samples 
tested using two techniques on both types of tumor 
specimen, 85% of cases were concordant (Supplementary 
Table S1).
The optimized cut-offs, the cut-offs allowing the 
best concordance between frozen and FFPE samples, 
and the cut-off of 8% for PSQ, as previously published 
in our retrospective series of GBM samples [10], were all 
included in the analysis. As shown in Tables 2, the higher 
optimal AUCROC values for OS and PFS, were obtained 
by using PSQ on FFPE or frozen samples whatever the 
cut-offs tested, except using FFPE samples with the cut-
off optimized on frozen samples (6% in this series) which 
resulted in a lower value.
The percentages of patients classified as 
“methylated” when employing a cut-off of 8% for PSQ 
were 49% for frozen samples and 51% for FFPE samples. 
Moreover, when utilizing a cut-off of 12%, the results 
were 44 and 41%, respectively. Using the sqMS-PCR 
method at a cut-off of 13% resulted in 45% of patients 
being classified as “methylated” in the frozen samples set 
and 37% in the FFPE sample set (Table 2). Kaplan-Meier 
survival curves displaying the OS and PFS of patients 
dichotomized according to these cut-offs are presented 
in Figure 4 and 5. Further evaluation of the optimal cut-
off for PSQ between 8% and 12% was investigated by 
examining the Kaplan Meier survival plots for patients 
categorized in three groups: (0%-8%), (9%-12%) and 
(13-100%). Patients with methylation between 9-12% had 
a better OS than patients with a methylation of less than 
or equal to 8%. A similar trend was observed for PFS, 
however only when the analysis was performed on frozen 
samples (Figure 6).
DISCUSSION
The French National Cancer Institute (INCa) 
and the French Ministry of Health have established a 
national network of regional molecular genetics centers, 
located throughout the country, to provide patient access 
to effective molecular testing. Therefore, the selected 
tests are required to be robust and reproducible (i.e. give 
Type of 
analysis type of cut-off cut-off value
% of patients 
with a methylated 
MGMT promoter
HR p AUCROC CHarrell
qMS-PCR/
FFPE
optimized cut-off for 
PFS (current series/
FFPE samples)
23 31 0,31 1,00E-06 0,64 0,62
qMS-PCR/
frozen
optimized cut-off for 
PFS (current series/
frozen samples)
13 45 0,42 2,28E-04 0,64 0,60
PSQ/FFPE
optimized cut-off for 
OS (current series/
frozen samples)
6 59 0,39 1,30E-05 0,63 0,61
qMS-PCR/
FFPE
best level of 
concordance 
between frozen and 
FFPE samples
13 37 0,37 6,00E-06 0,63 0,61
qMS-PCR/
FFPE
best level of 
concordance 
between frozen and 
FFPE samples
12 40 0,4 2,20E-05 0,62 0,60
In regards to each specific technique, different cut-offs were evaluated to determine the associated Hazard ratio (HR) 
and the level of significance (represented by the p value, which is to compare to 1.3/1000 with the multiple comparison 
correction of Bonferroni), after adjustment on age and Karnofsky score. The prediction errors were globally evaluated 
and reported as the Area Under the ROC Curve (AUCROC) and the Harrell’s C index. Results are classified according 
to the AUCROC result, from the highest to the lowest value. The same analysis was done for overall survival (OS/a) and 
progression free survival (PFS/b).
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comparable results in all laboratories). This prospective 
study was designed to validate a test method that allows 
for the quantification of MGMT methylation in routine 
clinical practice. PSQ and sqMS-PCR were two methods 
chosen to pursue after a preliminary retrospective study 
[10]. Both techniques evaluated in this study, resulted 
in good interlaboratory reproducibility for two of three 
methylated cell lines tested. The level of methylation of the 
third cell line was comparable to the limit of quantification 
previously established at 4% for PSQ [10] and 15% for 
sqMS-PCR [17], which explains the lower interlaboratory 
reproducibility. For this control, reproducibility was 
acceptable for the PSQ method. However; this was not 
the case for the sqMS-PCR method. These data strengthen 
the high interlaboratory reproducibility of PSQ with 
the commercial assay used for this study, even for low 
levels of methylation. To our knowledge, this is the first 
analysis of this type that has been performed in multiple 
Figure 4: Kaplan-Meier analysis of overall survival (OS) according to MGMT promoter methylation status. M: patients 
with a value above the calculated cut-off and therefore considered as methylated; UM: patients with a value below or equal to the calculated 
cut-off and therefore considered as unmethylated.
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laboratories. Previously, a similar conclusion for the 
PSQ method had been determined by Preusser et al 
after comparing results obtained from two independent 
laboratories [18].
Additionally, the parallel analysis of frozen and 
FFPE samples was a unique feature to the study. PSQ 
and sqMS-PCR were feasible in 81% (112/139) and 
78% (108/139) of cases on frozen samples and in 87% 
(121/139) and 85% (118/139) of cases on FFPE samples. 
The two major reasons preventing the analysis of frozen 
samples were the quality criteria concerning the minimal 
percentage of tumor cells (for 12% (15/127) of cases) 
and the lack of samples (for 9% (12/139) of cases). 
Moreover, the two reasons preventing analysis of FFPE 
samples were the lack of samples and failure analysis 
(7 cases with PSQ/8 cases with sqMS-PCR). It is worth 
mentioning that the rates of failure analysis for PSQ and 
sqMS-PCR were not consistent among centers, indicating 
Figure 5: Kaplan-Meier analysis of progression free survival (PFS) according to MGMT promoter methylation status. 
M: patients with a value above the calculated cut-off and therefore considered as methylated; UM: patients with a value below or equal to 
the calculated cut-off and therefore considered as unmethylated.
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a possible difference of technique execution among the 
laboratories. At the initiation of the study, some of the 
centers had already implemented one technique locally to 
analyze MGMT methylation. In our personal experience 
on over 200 FFPE-GBM samples, failure analysis was 
only observed with PSQ on older samples. For these cases, 
PSQ resulted in non-reproducible, false-positive results 
(unpublished data). In these particular cases of archived 
specimens with inconsistent quality dependent on fixation 
and storage conditions, it is strongly recommended to 
perform a DNA quality control check prior to the analysis. 
Overall, we confirm that FFPE samples are appropriate for 
MGMT analysis of GBM patients.
Cut-offs of 12% or 13% for PSQ and 13% for sqMS-
PCR allowed the best concordance values of 98% and 91% 
respectively to dichotomize patients as “methylated” and 
“unmethylated”. Recently, high concordance results using 
the PSQ method in comparison to the MS-PCR method, 
Figure 6: Kaplan-Meier analysis of overall survival (OS) and progression free survival (PFS) according to MGMT 
promoter methylation status tested by PSQ with a classification in three groups: “unmethylated” (0-8%), “methylated” 
(13-100%) and a grey zone for patients with intermediate values (9-12%).
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on both frozen and FFPE tissues, has been reported [19]. 
Globally a convincing correlation was observed between 
the values obtained with the two types of samples, either 
with PSQ or sqMS-PCR, highlighting the intratumoral 
homogeneity of MGMT promoter methylation, as 
previously described using serial stereotactic GBM 
samples [20].
One of the major objectives of this study was 
to establish optimal predictive cut-off values. To our 
knowledge, this is the first time that such values have 
been optimized on frozen and paired FFPE samples on 
a prospective cohort of patients. Using the sqMS-PCR 
method a previous study recommended to classify as 
«unmethylated» samples with a ratio lower than 15% 
(<15%) and a ratio of 30% identified GBM patients 
with a long PFS [17]. Remarkably, our results showed 
that 13% (less than or equal to 13%) allowed for the 
best concordance of classification between frozen 
and FFPE samples as well as the best distinction for 
survival when considering results on frozen samples; 
which validates a cut-off of approximately 13%-15% 
to dichotomize patients. However, poor interlaboratory 
reproducibility was observed at these values. Analytical 
performances must therefore be carefully examined by 
each laboratory before utilizing this technique in a clinical 
setting. Furthermore a classification of three groups 
can be recommended, particularly with FFPE samples: 
«unmethylated» samples (ratio <=13%), samples with 
low methylation (between 14-23%), “methylated” samples 
(>23%).
In a recent review about MGMT methylation 
pyrosequencing in glioblastoma, more than 20 studies 
have been reported. In the majority of cases, the thresholds 
were between 8 and 10% [21]. Our prospective study 
validates a cut-off of 8% to predict poor response to 
TMZ treatment. It is interesting to notice that there have 
not been any survival improvements in the past years on 
patients lacking a significant level of MGMT methylation. 
In our retrospective cohort of 100 patients having received 
the standard “Stupp” protocol between 2004 and 2007, 
“unmethylated” patients (<=8%) had a median PFS of 
9 months and a median OS of 15.7 months, which is 
comparable to the values obtained for the “unmethylated” 
patients of this study treated between 2009 and 2011 (8.4 
and 15.9 months respectively). Additionally, “methylated” 
patients had comparable PFS (14.6 and 15.1 months) but 
a large improvement was observed for OS, which was 
26.2 months in the previous study and 34.7 months in 
the current one. This data indicates that “methylated” 
patients may significantly benefit from new second-line 
treatments when compared to “unmethylated” patients. 
Because higher thresholds performed better when 
analyzing FFPE samples, we proposed as a second cut-
off the value of 12%, at which an excellent concordance 
was observed between FFPE and frozen samples. Patients 
above 12% could be considered as “methylated”, while 
patients between 9 and 12% may be considered to have 
a moderate/low methylation pattern. The intermediate 
values pose a challenge as no conclusive evidence can be 
interpreted in this study to conclude a clear benefit from 
TMZ treatment, although these patients did present a 
better OS than “unmethylated” patients. This interval of 
values could therefore be considered a “grey zone”.
In summary, we performed a prospective multicentre 
trial in newly-diagnosed GBM patients homogeneously 
treated. Our data indicated that MGMT status can be 
reliably evaluated on both FFPE or frozen samples in local 
laboratories. There are advantages to investigating FFPE 
samples in routine clinical practice: samples are almost 
always available and selection of non necrotic areas can be 
easily performed. Furthermore that helps to preserve fresh 
frozen brain samples for alternative purposes. sqMS-PCR 
is a viable option for MGMT testing, particularly if there is 
a lack of a pyrosequencer. However, our data demonstrate 
PSQ is the ideal choice because of its robustness, which 
was shown by the strong interlaboratory reproducibility. 
Additionally, the PSQ method offers increased sensitivity 
and several independent studies have been concordant in 
the threshold levels that discriminate between methylated 
and non-methylated patients.
MATERIALS AND METHODS
Patients
Patients were enrolled for this study between the 
dates of March 11, 2009 and June 29, 2011 from 8 French 
centers. Eligible patients had histologically confirmed 
de novo-glioblastoma, were between the ages of 18-70, 
presented with no contraindications as dictated by the 
Stupp protocol and were not included in experimental 
therapeutic protocols. Histological diagnoses were 
confirmed centrally by 3 pathologists: DFB, EL and DC. 
The protocol was approved by the Rennes medical ethics 
committee and informed consent was obtained from each 
patient.
MGMT promoter methylation analysis
In a first step of the protocol, Standard Operating 
Procedure (SOP) for the determination of MGMT 
promoter methylation were sent to the different centers 
as well as 10 quality control samples: 5 samples with 
DNA extracted from peripheral blood mononuclear cells 
and from 4 primary cell lines and 5 samples with the 
same bisultite converted DNA. This step allowed for the 
standardization of the process throughout the multiple 
centers. Additionally, DNA extracted from 3 primary cell 
lines (RNS85, RNS96 and RNS175) were used as external 
quality controls in each of the centers and were tested in 
each series of tests. The coefficient of variation (CV) was 
calculated to determine reproducibility.
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DNA extractions from clinical samples, as well as 
sodium bisulfite treatment, were performed in each center 
according to local procedures. Frozen samples with a 
histologically estimated tumor cell content below 40% 
were excluded from the study. In regards to FFPE samples, 
if necessary, macro-dissection was performed to enrich 
tumor cell content.
PSQ was performed as previously described [10, 
12] using the PyroMark CpG MGMT kit (ref. 972032, 
Qiagen, France). All assays were performed in duplicate 
and each result was averaged together. The average 
percentage of the 5 CpGs tested was considered. sqMS-
PCR was performed with primers specific for either 
“methylated” or “unmethylated” DNA. Forward primers 
were labeled at their 5’ end with a fluorescent reporter 
dye (FAM), as previously described [17]. The PCR 
products corresponding to the “methylated” sequences 
have a size of 82bp while the “unmethylated” sequences 
have 12 additional nucleotides (94bp). Both fragments 
were amplified in the same reaction and PCR products 
were analyzed by capillary electrophoresis. Estimation 
of the amount of methylated DNA was calculated with 
the following formula, abbreviations are as follows; MF-
“methylated” fraction, UM-“unmethylated” fraction:
(peak height of the MF/peak height of the UM + MF) × 100.
Statistical analysis
Statistical analysis was performed using R statistical 
software (version 2.13.0, http://www.Rproject.org). 
Optimal risk cut-offs were determined as previously 
described with age and performance status introduced 
as adjustment factors [10]. The function risksetAUC 
(package risksetROC) in the R statistical software was 
used to obtain the area under the ROC curve. Additionally, 
the Harrell’s C index [22] was calculated using the 
validate function (in Design package). To study OS and 
PFS, cumulative event curves (censored endpoints) were 
established using the Kaplan-Meier method.
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